AI assistant
Innoviva, Inc. — Director's Dealing 2012
Nov 7, 2012
32090_dirs_2012-11-06_3a07831e-dd1c-4cd3-b4c2-400bd9d9bd73.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2012-11-02
Reporting Person: Mammen Mathai (SVP, Research & Early Clin Dev)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-11-02 | Common Stock | S | 6800 | $21.42 | Disposed | 205841 | Direct |
| 2012-11-02 | Common Stock | S | 200 | $22.53 | Disposed | 205641 | Direct |
Footnotes
F1: Dispositions made pursuant to a plan intended to comply with rule 10b5-1(c).
F2: This transaction was executed in multiple trades at prices ranging from $21.08 to $22.03 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $22.49 to $22.56. The price reported above reflects the weighted average sale price.